Thomas L. Wenger - Concepedia

Author

Thomas L. Wenger

Duke Medical Center

Also Known As

T L Wenger, THOMAS L WENGER, THOMAS L. WENGER, Thomas L. Wenger, Thomas Wenger

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Duke Medical Center Duke University Duke University Hospital University of British Columbia Burroughs Wellcome Fund

About

Thomas L. Wenger is an author at Duke Medical Center specializing in medicine, cardiovascular disease, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	846
2	Public Health	4	4	291
3	Social Sciences	2	2	65
4	Health Sciences	1	1	36
5	Anesthesia	1	1	20

Thomas L. Wenger

Publications

Citations

H-Index

Page 1

	Year	Citations
Risk stratification after acute myocardial infarction J. Thomas Bigger, Caren Heller, Thomas L. Wenger, The American Journal of Cardiology Cardiovascular EpidemiologyCardiovascular DiseaseAtherosclerosisClinical EpidemiologyAcute Myocardial Infarction	1978	228
Digoxin Immune Fab therapy in the management of digitalis intoxication: Safety and efficacy results of an observational surveillance study Anne R. Hickey, Thomas L. Wenger, Vincent P. Carpenter, Journal of the American College of Cardiology Autoimmune DiseaseImmunotoxicologyDigital TherapeuticsObservational Surveillance StudyImmunology	1991	188
Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments Thomas L. Wenger, Vincent P. Butler, Edgar Haber, Journal of the American College of Cardiology Autoimmune DiseaseDigoxin-specific Antibody FragmentsImmunodeficienciesHematologyImmunology	1985	174
The Use of Digoxin-Specific Fab Fragments for Severe Digitalis Intoxication in Children Alan D. Woolf, Thomas L. Wenger, Thomas W. Smith, New England Journal of Medicine	1992	101
The Cardiovascular Effects of Bupropion and Nortriptyline in Depressed Outpatients Ari Kiev, H. L. Masco, Thomas L. Wenger, Annals of Clinical Psychiatry HypertensionPsychotropic MedicationPsychopharmacologyPharmacotherapyBlood Pressure	1994	50
Cost-effectiveness analysis of the use of digoxin immune Fab(ovine) for treatment of digoxin toxicity Josephine Mauskopf, Thomas L. Wenger The American Journal of Cardiology Cost-effectiveness AnalysisDigoxin ToxicityDigoxin Immune FabImmunotoxicologyImmunology	1991	41
Changes of Adrenergic Reaction Pattern in Experimental Diabetes Mellitus Regina Cseuz, Thomas L. Wenger, George Kunos, Endocrinology Adrenergic Reaction PatternIntegrative PhysiologyMolecular PharmacologyMetabolic SyndromeAdrenal Gland	1973	36
Hypersensitive Carotid Sinus Syndrome Manifested as Cough Syncope Thomas L. Wenger, Mary L. Dohrmann, Harold C. Strauss, Pacing and Clinical Electrophysiology	1980	31
Limitations of the Lown grading system for the study of human ventricular arrhythmias J. Thomas Bigger, Thomas L. Wenger, Robert H. Heissenbuttel American Heart Journal CardiomyopathyHeart FailureRadiologyElectrophysiological EvaluationCardiovascular Disease	1977	30
Experience with digoxin immune Fab (ovine) in patients with renal impairment Thomas L. Wenger The American Journal of Emergency Medicine InflammationGlomerulonephritisUrologyRenal FunctionAutoimmune Disease	1991	29

Page 1